Page 4 - Iontech News Today

STOCKHOLM (Reuters) -Hungarian scientist Katalin Kariko and U.S. colleague Drew Weissman, who met in line for a photocopier before making mRNA molecule discoveries that paved the way for COVID-19 vaccines, won the 2023 Nobel Prize for Medicine on Monday. The prize, among the most prestigious in the scientific world, was selected by the Nobel Assembly of Sweden's Karolinska Institute medical university and comes with 11 million Swedish crowns (about $1 million) to share between them. Kariko,...

STOCKHOLM (Reuters) -Hungarian scientist Katalin Kariko and U.S. colleague Drew Weissman, who met in line for a photocopier before making mRNA molecule discoveries that paved the way for COVID-19 vaccines, won the 2023 Nobel Prize for Medicine on Monday. The prize, among the most prestigious in the scientific world, was selected by the Nobel Assembly of Sweden's Karolinska Institute medical university and comes with 11 million Swedish crowns (about $1 million) to share between them. Karik...

Nobel Prize winners Katalin Karikó and Drew Weissman harnessed messenger RNA, an advance that led to the Pfizer and Moderna COVID-19 vaccines.

This year’s Nobel Prize in physiology or medicine has been awarded to Katalin Karikó and Drew Weissman for their work on mRNA vaccines.

Professors Katalin Karikó and Drew Weissman published a paper in 2005 that showed the mRNA could be modified to create more effective vaccines.

Uganda and the continent in general, shoulders a heavy disease burden yet the world scientific output focused on African countries remains largely small estimated at less than 1 per cent.

We previously reported on patent infringement litigations between Alnylam and Moderna. Below we provide updates on two proceedings involving the mRNA vaccine producer Moderna.

BioNTech would initiate an early-to-mid stage trial for the vaccine program BNT166 to prevent mpox, a viral illness that causes skin rashes and could be transmitted to humans through physical contact. The vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in its COVID shots developed with partner Pfizer. The partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) also aims to contribute to its mission to accelerate development of va...

BioNTech would initiate an early-to-mid stage trial for the vaccine program BNT166 to prevent mpox, a viral illness that causes skin rashes and could be transmitted to humans through physical contact. The vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in its COVID shots developed with partner Pfizer. The partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) also aims to contribute to its mission to accelerate development of vacc

WILMINGTON, Del., Sept. 17, 2023 (GLOBE NEWSWIRE) -- In the ever-evolving landscape of construction, AC3D is pushing the boundaries of whats possible...